Industry

 A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic and operational roadmap for future commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation … [Read more…]

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on Sanofi’s proprietary multifunctional CROSSDILES® platform and Innate’s proprietary multi-specific NK cell engager platform, ANKETTM targeting BCMA, selected by Sanofi for IND-enabling studies, with €3M milestone payment … [Read more…]

Leadership team reinforced for next phase in Protembis’ clinical and regulatory growth trajectory AACHEN, Germany–(BUSINESS WIRE)–#CerebralProtection—Protembis GmbH, a privately-held emerging cardiovascular medical device company, announced today the appointment of highly experienced and successful serial entrepreneur and medical device executive Azin Parhizgar (Ph.D.) as an Independent Member and Chairwoman of the Board of Directors. Azin remains … [Read more…]

CHICAGO–(BUSINESS WIRE)–The Chicago Chapter of the Dragonfly Foundation received a $5,000 grant from the SBB Research Group Foundation, which awards monthly grants to support impactful organizations during the pandemic. The Dragonfly Foundation partners with local hospitals to fulfill the everyday needs of children with cancer and their families. Since 2010, the Cincinnati-headquartered nonprofit has assisted … [Read more…]

BEIJING & GUANGZHOU, China–(BUSINESS WIRE)–#Biocytogen–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell … [Read more…]

Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) The phase 1/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors SEONGNAM-SI, South Korea–(BUSINESS WIRE)–#Qurient—Qurient Co. Ltd. (KRX: 115180), a clinical-stage … [Read more…]

GROTON, Conn.–(BUSINESS WIRE)–Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore Liston, Ph.D., Vice President … [Read more…]

FRAMINGHAM, Mass.–(BUSINESS WIRE)–#autoimmune–Clinical Enterprise, Inc. d/b/a empowerDX, who offers the at-home Celiac Risk Gene Test, announced today that they have entered into an exclusive partnership with NIMA Partners, the makers of Gluten Sensor and Gluten Capsules for the detection of gluten in food particles. This partnership is characteristic of the ethos defining the mission of … [Read more…]

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference. The presentation is scheduled for September 28, 2022 at 11:15am ET. A webcast … [Read more…]

Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation JUNCTION CITY, Kan.–(BUSINESS WIRE)–#biotech—Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara’s previous determination and affirmed the prior ruling that … [Read more…]